|
|
xvii | |
Foreword |
|
xxv | |
|
Part 1 Research methodology for clinical trials, animal research, and retrospective studies |
|
|
|
1 Reliability and validity in substance misuse and addiction research |
|
|
3 | (8) |
|
|
|
|
|
3 | (1) |
|
|
3 | (2) |
|
|
4 | (1) |
|
|
4 | (1) |
|
|
5 | (1) |
|
|
5 | (3) |
|
|
6 | (1) |
|
|
6 | (1) |
|
|
7 | (1) |
|
|
7 | (1) |
|
|
7 | (1) |
|
|
8 | (3) |
|
|
11 | (12) |
|
|
|
|
|
|
11 | (1) |
|
|
11 | (2) |
|
Intravenous drug self-administration |
|
|
12 | (1) |
|
|
12 | (1) |
|
Intracranial self-administration |
|
|
13 | (1) |
|
Operant vapor self-administration |
|
|
13 | (1) |
|
Schedules of reinforcement |
|
|
13 | (2) |
|
Ratio and interval schedules of reinforcement |
|
|
13 | (1) |
|
Second-order schedules of reinforcement |
|
|
14 | (1) |
|
Progressive-ratio schedules of reinforcement |
|
|
14 | (1) |
|
Conditioned place preference |
|
|
15 | (1) |
|
|
16 | (2) |
|
|
17 | (1) |
|
|
17 | (1) |
|
|
17 | (1) |
|
|
17 | (1) |
|
Interpretation of drug discrimination |
|
|
18 | (1) |
|
Other topics in animal research |
|
|
18 | (2) |
|
|
18 | (1) |
|
Complex schedules of reinforcement |
|
|
19 | (1) |
|
|
19 | (1) |
|
|
20 | (3) |
|
3 Translational research strategies |
|
|
23 | (8) |
|
|
|
24 | (1) |
|
Neurobiology of substance use disorders and addictions |
|
|
25 | (1) |
|
|
26 | (1) |
|
|
26 | (1) |
|
|
27 | (1) |
|
|
28 | (3) |
|
4 Experimental designs for addiction research |
|
|
31 | (24) |
|
|
|
|
|
31 | (1) |
|
|
32 | (7) |
|
Foundations of experimental design |
|
|
33 | (1) |
|
|
34 | (1) |
|
General sample considerations |
|
|
35 | (1) |
|
|
35 | (3) |
|
Scales for the "measurement" of the severity of addiction |
|
|
38 | (1) |
|
Paper 2: observational study |
|
|
39 | (6) |
|
|
40 | (1) |
|
|
41 | (1) |
|
Scales and research scales for measurement |
|
|
42 | (3) |
|
|
45 | (1) |
|
Paper 3: experimental design |
|
|
45 | (5) |
|
Goals and hypothesis of the investigation |
|
|
46 | (1) |
|
|
47 | (1) |
|
|
48 | (1) |
|
|
49 | (1) |
|
|
50 | (1) |
|
|
51 | (4) |
|
5 Experimental design in clinical trials |
|
|
55 | (10) |
|
|
|
|
|
|
|
|
|
|
55 | (1) |
|
Target population and recruitment |
|
|
56 | (1) |
|
Sample size; outcome measures |
|
|
57 | (1) |
|
|
58 | (1) |
|
|
59 | (3) |
|
Diagnostic and statistical manual of mental disorders |
|
|
59 | (2) |
|
International classification of diseases |
|
|
61 | (1) |
|
Modes of data collection (surveys, interviews, etc.) |
|
|
62 | (1) |
|
|
62 | (1) |
|
Method of data collection |
|
|
62 | (1) |
|
|
63 | (1) |
|
|
64 | (1) |
|
6 Qualitative and quantitative research methods |
|
|
65 | (6) |
|
|
|
|
|
|
65 | (1) |
|
|
65 | (1) |
|
|
65 | (1) |
|
Collecting and organizing data |
|
|
66 | (3) |
|
|
66 | (1) |
|
Quantitative data collection methods |
|
|
66 | (1) |
|
Qualitative data collection methods |
|
|
67 | (1) |
|
|
67 | (1) |
|
|
68 | (1) |
|
|
69 | (1) |
|
|
69 | (2) |
|
7 Ethical issues in substance misuse and addiction-related research |
|
|
71 | (20) |
|
|
|
|
|
|
71 | (1) |
|
|
72 | (15) |
|
Addiction-specific ethical issues |
|
|
73 | (3) |
|
Substance misuse research ethics in other countries |
|
|
76 | (6) |
|
Funding for substance-use disorder research |
|
|
82 | (5) |
|
|
87 | (1) |
|
|
87 | (4) |
|
|
91 | (8) |
|
|
|
|
|
|
|
|
|
91 | (1) |
|
|
92 | (1) |
|
Clinical Research Informatics Applications |
|
|
93 | (3) |
|
|
96 | (1) |
|
|
97 | (2) |
|
9 Artificial intelligence and machine learning |
|
|
99 | (8) |
|
|
|
|
|
|
99 | (1) |
|
Natural language processing |
|
|
100 | (1) |
|
Applicability to addiction medicine |
|
|
100 | (2) |
|
Limitations and considerations |
|
|
102 | (1) |
|
|
103 | (1) |
|
|
104 | (3) |
|
10 Methods for data collection and analysis in epidemiology-of-substance-use research |
|
|
107 | (12) |
|
|
|
|
|
|
107 | (1) |
|
Large cross-section observational surveys |
|
|
108 | (1) |
|
National Survey of Drug Use and Health |
|
|
108 | (1) |
|
National Epidemiologic Survey on Alcohol and Related Conditions |
|
|
109 | (1) |
|
Monitoring the Future Study |
|
|
110 | (1) |
|
|
111 | (3) |
|
|
114 | (1) |
|
Genetic epidemiology study designs |
|
|
115 | (1) |
|
|
116 | (1) |
|
|
116 | (1) |
|
|
117 | (2) |
|
11 Utility of neuroimaging for substance misuse and addiction research: methodology, mechanisms, and therapeutics |
|
|
119 | (14) |
|
|
|
|
|
|
|
|
|
|
119 | (1) |
|
Structural magnetic resonance imaging and functional magnetic resonance imaging |
|
|
120 | (1) |
|
Magnetic resonance spectroscopy |
|
|
121 | (2) |
|
The role of magnetic resonance spectroscopy in substance misuse |
|
|
122 | (1) |
|
Positron emission tomography |
|
|
123 | (1) |
|
Single-photon emission computed tomography |
|
|
124 | (3) |
|
|
127 | (1) |
|
|
128 | (5) |
|
12 Systematic review and meta-analysis |
|
|
133 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 | (1) |
|
|
134 | (1) |
|
|
134 | (2) |
|
|
136 | (2) |
|
Examples of meta-analyses studying substance misuse risk factors |
|
|
138 | (2) |
|
Examples of meta-analyses studying substance misuse management |
|
|
140 | (1) |
|
|
141 | (1) |
|
|
142 | (5) |
|
Part 2 Mechanisms of drug misuse and addiction |
|
|
|
13 Misuse and addiction definitions, demographics, and general concepts |
|
|
147 | (14) |
|
|
|
|
147 | (3) |
|
Definition of substance-related and addiction disorders |
|
|
150 | (1) |
|
|
150 | (7) |
|
Alcohol-related disorders |
|
|
151 | (1) |
|
Amphetamines and amphetamine-related disorders |
|
|
152 | (1) |
|
Caffeine-related disorders |
|
|
152 | (1) |
|
Cannabis-related disorders |
|
|
153 | (1) |
|
Tobacco-related disorders |
|
|
153 | (1) |
|
|
154 | (1) |
|
Hallucinogen-related disorders |
|
|
155 | (1) |
|
Inhalant-related disorders |
|
|
155 | (1) |
|
Sedative-, hypnotic-, or anxiolytic-related disorders |
|
|
156 | (1) |
|
Unspecified other (or unknown) substance--related disorder |
|
|
156 | (1) |
|
|
156 | (1) |
|
General concepts and conclusion |
|
|
157 | (1) |
|
|
157 | (4) |
|
14 Assessment of addiction/pain and neurobiology |
|
|
161 | (16) |
|
|
|
|
|
|
161 | (1) |
|
Assessing different forms of pain |
|
|
161 | (4) |
|
|
163 | (2) |
|
|
165 | (4) |
|
Addiction assessment tools |
|
|
165 | (4) |
|
|
169 | (2) |
|
The neurobiology of addiction |
|
|
171 | (1) |
|
Mesocorticolimbic dopaminergic system |
|
|
171 | (1) |
|
The hypothalamic--pituitary-adrenal axis |
|
|
171 | (1) |
|
|
172 | (5) |
|
15 Physiological considerations in opioid addiction |
|
|
177 | (8) |
|
|
|
|
|
|
|
|
|
177 | (1) |
|
Normal physiology and anatomy |
|
|
178 | (1) |
|
Pathophysiologic considerations |
|
|
179 | (1) |
|
|
179 | (1) |
|
Neurotransmitters and projections |
|
|
180 | (1) |
|
|
181 | (1) |
|
|
182 | (1) |
|
|
182 | (1) |
|
|
183 | (2) |
|
16 Basic pharmacology of opioid substances |
|
|
185 | (24) |
|
|
|
|
|
|
|
185 | (1) |
|
|
186 | (12) |
|
|
186 | (6) |
|
|
192 | (4) |
|
|
196 | (2) |
|
Elimination and excretion |
|
|
198 | (1) |
|
|
198 | (1) |
|
|
199 | (5) |
|
|
204 | (5) |
|
17 Basic pharmacology of nonopioid substances |
|
|
209 | (24) |
|
|
|
|
|
|
|
|
209 | (1) |
|
|
209 | (2) |
|
|
211 | (2) |
|
|
213 | (2) |
|
Sedatives and tranquilizers |
|
|
215 | (11) |
|
|
215 | (1) |
|
|
216 | (4) |
|
|
220 | (6) |
|
|
226 | (7) |
|
|
233 | (32) |
|
Michelle A. Carroll Turpin |
|
|
|
|
|
|
|
|
|
|
|
|
|
233 | (1) |
|
|
234 | (1) |
|
|
235 | (13) |
|
|
235 | (2) |
|
|
237 | (1) |
|
|
238 | (2) |
|
|
240 | (2) |
|
|
242 | (2) |
|
|
244 | (2) |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
248 | (4) |
|
|
252 | (13) |
|
|
265 | (10) |
|
|
|
|
|
265 | (1) |
|
|
266 | (2) |
|
|
266 | (1) |
|
What is substance use, misuse, and disorder? |
|
|
267 | (1) |
|
|
267 | (1) |
|
Risk factors and protective factors to substance misuse |
|
|
268 | (1) |
|
Diagnosis of substance misuse |
|
|
269 | (2) |
|
|
269 | (1) |
|
Medical understanding and misunderstandings |
|
|
270 | (1) |
|
|
271 | (1) |
|
|
271 | (4) |
|
20 Special study populations |
|
|
275 | (14) |
|
|
|
|
|
|
275 | (1) |
|
|
276 | (2) |
|
|
277 | (1) |
|
|
277 | (1) |
|
Neuroactive gonadal steroid hormones |
|
|
278 | (1) |
|
Gender differences in stress reactivity and relapse to substance misuse |
|
|
278 | (1) |
|
Effects and complications |
|
|
278 | (1) |
|
|
278 | (3) |
|
|
279 | (1) |
|
Behavior, affect, and temperament |
|
|
279 | (1) |
|
|
279 | (1) |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
280 | (1) |
|
|
281 | (2) |
|
|
281 | (1) |
|
|
282 | (1) |
|
Medications and illicit drugs |
|
|
283 | (1) |
|
Improving the quality of life of the geriatric population with substance misuse |
|
|
283 | (1) |
|
|
283 | (1) |
|
|
284 | (1) |
|
|
285 | (4) |
|
Part 3 Investigative therapeutics: designing and measuring outcomes |
|
|
|
21 General therapy strategies in opioid addiction |
|
|
289 | (20) |
|
|
|
|
|
|
|
|
|
289 | (1) |
|
Therapy and groups for treatment of opioid use disorder |
|
|
290 | (2) |
|
|
290 | (1) |
|
Mutual help groups and 12-step facilitation |
|
|
290 | (1) |
|
Reinforcement-based treatment |
|
|
291 | (1) |
|
|
291 | (1) |
|
Other individual-based therapy |
|
|
292 | (4) |
|
Mindfulness and relaxation-based therapy |
|
|
292 | (1) |
|
Psychodynamic psychotherapy |
|
|
293 | (1) |
|
|
293 | (1) |
|
Cognitive behavioral therapy |
|
|
294 | (1) |
|
Community reinforcement approach |
|
|
295 | (1) |
|
|
296 | (1) |
|
Medication-assisted treatment |
|
|
296 | (2) |
|
|
296 | (1) |
|
|
297 | (1) |
|
|
298 | (1) |
|
|
298 | (1) |
|
|
299 | (3) |
|
|
300 | (1) |
|
Chronic pain in patients with opioid use disorder |
|
|
301 | (1) |
|
|
302 | (1) |
|
|
303 | (4) |
|
|
307 | (2) |
|
22 The role of alternative therapies in a comprehensive addiction treatment |
|
|
309 | (14) |
|
|
|
309 | (1) |
|
|
309 | (1) |
|
Neurobiological evidence of addiction |
|
|
310 | (1) |
|
The role of complementary alternative medicine in the treatment of addictions |
|
|
311 | (6) |
|
Strategy for implementing acupuncture as part of the rehabilitation program |
|
|
317 | (1) |
|
|
318 | (5) |
|
23 Drug testing and adherence monitoring |
|
|
323 | (10) |
|
|
|
|
|
|
|
|
|
323 | (1) |
|
Biological specimens that can be drug tested with a focus on urine |
|
|
324 | (1) |
|
|
325 | (1) |
|
|
325 | (1) |
|
Gas chromatography/mass spectrometry |
|
|
326 | (1) |
|
Liquid chromatography/mass spectrometry |
|
|
326 | (1) |
|
Metabolism of illicit and prescribed drugs |
|
|
326 | (4) |
|
Important clinical findings |
|
|
327 | (3) |
|
|
330 | (1) |
|
|
331 | (2) |
|
24 Pharmacogenetics: a comprehensive review of genes, genetics, genomics, and epigenetics |
|
|
333 | (16) |
|
|
|
|
|
|
|
|
|
|
|
333 | (1) |
|
Alcohol use, metabolism, and pharmacogenetics |
|
|
334 | (2) |
|
Opioid use, metabolism, and pharmacogenetics |
|
|
336 | (2) |
|
Nicotine use, metabolism, and pharmacogenetics |
|
|
338 | (1) |
|
Pharmacogenetics and epigenetics studies |
|
|
339 | (4) |
|
Genetic polymorphisms, responses to treatment, and risk for conditions |
|
|
339 | (1) |
|
Importance of the availability of genetic data to improve patient outcomes |
|
|
340 | (1) |
|
Genetic variants linked with perioperative complications |
|
|
341 | (1) |
|
Social adversity and socioeconomic status in relation to epigenetic aging |
|
|
341 | (2) |
|
|
343 | (1) |
|
|
344 | (5) |
|
25 Medical treatments for opioid use disorder |
|
|
349 | (20) |
|
|
|
|
|
349 | (2) |
|
Opioid overdose: detection and intervention |
|
|
351 | (1) |
|
Opioid withdrawal symptoms: assessment and treatment |
|
|
352 | (4) |
|
Opioid withdrawal: time course and assessment |
|
|
352 | (1) |
|
Opioid withdrawal and management (detoxification) |
|
|
353 | (3) |
|
Current consensus on the role of opioid withdrawal management (detoxification) |
|
|
356 | (1) |
|
Medications for opioid use disorder |
|
|
356 | (6) |
|
|
356 | (1) |
|
|
356 | (2) |
|
|
358 | (1) |
|
|
359 | (1) |
|
Treatment considerations in special populations |
|
|
360 | (1) |
|
Role of urine drug monitoring in treatment |
|
|
361 | (1) |
|
Role of psychosocial interventions in opioid use disorder treatment |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
363 | (6) |
|
26 Principles of vaccine development |
|
|
369 | (10) |
|
|
|
|
|
|
|
|
369 | (1) |
|
|
370 | (1) |
|
|
370 | (1) |
|
|
370 | (1) |
|
|
370 | (1) |
|
|
371 | (1) |
|
Food and Drug Administration recommendations |
|
|
371 | (5) |
|
Recommendations for three common study types |
|
|
372 | (1) |
|
Clinical efficacy and safety |
|
|
372 | (2) |
|
|
374 | (2) |
|
|
376 | (1) |
|
|
377 | (2) |
|
|
379 | (10) |
|
|
|
|
|
|
|
|
|
|
379 | (1) |
|
Comparative drug policy analysis |
|
|
380 | (1) |
|
Drug policies versus laws |
|
|
381 | (1) |
|
|
382 | (1) |
|
Health impact of drug policy based on enforcement of prohibition |
|
|
383 | (2) |
|
Criminal networks and interpersonal violence |
|
|
384 | (1) |
|
|
384 | (1) |
|
Increased burden of disease |
|
|
384 | (1) |
|
Racial discrimination and incarceration |
|
|
385 | (1) |
|
|
385 | (1) |
|
|
385 | (4) |
|
28 Designing and testing population-based prevention programs |
|
|
389 | (12) |
|
|
|
|
|
|
|
389 | (1) |
|
Why do most drug prevention programs fail? |
|
|
390 | (1) |
|
School-based prevention programs |
|
|
391 | (4) |
|
Advances and future directions for population-based prevention programs |
|
|
395 | (1) |
|
|
396 | (1) |
|
|
397 | (4) |
|
29 New vistas in addiction therapy |
|
|
401 | (10) |
|
|
|
401 | (1) |
|
|
401 | (1) |
|
|
402 | (1) |
|
|
403 | (1) |
|
|
403 | (1) |
|
|
403 | (1) |
|
|
404 | (1) |
|
Buprenorphine implants and depot injections |
|
|
405 | (3) |
|
The perverse economics of opiate maintenance programs |
|
|
408 | (1) |
|
|
409 | (1) |
|
|
409 | (1) |
|
|
410 | (1) |
Index |
|
411 | |